Engitix
Biotech / extracellular matrix drug discovery, London
Develops ECM-targeted therapies for cancer and fibrosis using human tissue data. It raised £20m in its Series A in January 2026. It has 4 roles open, 4 of them in the UK.
Backed by Netherton Investments.
On the Home Office register of licensed visa sponsors.
- 38 daystypical age of an open role
- 1roles open for more than 60 days
- 1roles taken down since we started tracking
- 0%of roles list a salary
Open roles
4 live todayOpen roles over time
Hiring momentum
Roles per weekAdded (by posting date)Closed (removed from the board)In the news (hover for headline)
Open roles by function
Open roles by team
As the company labels themIn the news
All 21 stories- Partnerships & dealsStreetInsider, 7 days agoPrimary Sclerosing Cholangitis Pipeline Update 2026: Clinical Development Status, Collaborations, and Key Companies to Watch | Engitix, GRI Bio, Qing Bile Therapeutics, Sirnaomics, Cascade Pharma
- LeadershipPulse 2.0, 19 days agoEngitix Appoints Former BioNTech Executive Ryan Richardson To Board Of Directors
- LeadershipPMLiVE, 23 Sept 2026Engitix appoints Sonia Quaratino as EVP Chief Medical Officer
- Partnerships & dealsPharmafile, 28 Jul 2026Lonza and Engitix partner to develop next-generation antibody-drug conjugates
- ExpansionGenetic Engineering and Biotechnology News, 22 Jul 2026Engitix Licenses Lonza’s Technology to Advance ADC Therapies
- OtherThe Healthcare Technology Report., 22 Jul 2026Engitix’s Giuseppe Mazza is Looking Beyond the Cell